List view / Grid view
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
